Numerous Indian American STEM Researchers Named Fellows of American Association for the Advancement of Sciences indiawest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiawest.com Daily Mail and Mail on Sunday newspapers.
Stupid Strong Charitable Foundation Pledges $250,000 to Support Gastric Cancer Research at MD Anderson Cancer Center
News provided by
Share this article
Share this article
FORT-WORTH, Texas, Dec. 23, 2020 /PRNewswire/ Stupid Strong Charitable Foundation is proud to contribute $250,000 to The University of Texas MD Anderson Cancer Center to support cutting-edge research in gastric cancer led by Jaffer Ajani, M.D., professor of Gastrointestinal Medical Oncology. The gift is made in partnership with the Cless Family Foundation. We re thrilled to be able to support this research, said Jen Cless Zehr from the Cless Family Foundation. Early detection, discerning discoveries and novel treatments will make the prognosis of gastric cancer change from dire to hopeful.
Published: Dec 23, 2020
SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/
Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (ClinicalTrials.gov Identifier: NCT04305795) has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas. Approximately 74 patients are planned for this trial in Head and Neck Squamous Cell Carcinoma (HNSCC) and Cutaneous Squamous Cell Carcinoma (CuSCC).
The trial will enroll three cohorts of patients within distinct populations – all with locally advanced, recurrent and/or metastatic HNSCC or locally advanced or metastatic CuSCC. Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy.
Search jobs 23-Dec-2020 Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (ClinicalTrials.gov Identifier: NCT04305795) has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas. Approximately 74 patients are planned for this trial in Head and Neck Squamous Cell Carcinoma (HNSCC) and Cutaneous Squamous Cell Carcinoma (CuSCC).
email article
Triple-negative breast cancer (TNBC) has been one of the most difficult cancers to treat mainly because it doesn t offer much in the way of therapeutic targets, but that is starting to change. Triple-negative breast cancer, for many years at least, has not had a clear target that we can attack, Debu Tripathy, MD, chairman of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, told
MedPage Today. It has always been a challenging subtype to treat. For hormone-receptor positive cancers we can use endocrine therapies, he explained. For HER2-positive cancers we can use HER2-targeted therapies, and these are quite effective. We still use chemotherapy in many of these cases, but we get an added advantage with the addition of the targeted agents. But for triple-negative, we haven t been able to find a very specific, unique target that can be harnessed as a drug.